Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
18 Years
N/A
Both
Liver Cancer
Trial Information
Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
Liver cancer is a deadly cancer that is typically hard to diagnose and treat. The currently
used blood marker for the clinical diagnosis of liver cancer is alpha-feto protein (AFP),
which misses 40-60% of patients with liver cancer because it lacks sufficient specificity
and sensitivity. The purpose of this study is to identify blood markers that have the
ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in
conjunction with AFP. The aim of this study is to identify new blood markers of liver cancer
that can be used to increase the rate of accurate diagnosis of this malignancy.
Inclusion Criteria:
Patients diagnosed with liver cancer based on biopsy or serum AFPlevel, associated with characteristic hypervascular liver tumors on triphasic spiral CT
scan or MRI.
- Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or
nodular hyperplasia.
- Patients with hepatitis B or hepatitis C viral infections not associated with liver
cancer.
Exclusion Criteria:Patients will be excluded if, upon looking through their medical
records, information required for data analysis are missing.
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Principal Investigator
Samuel So
Investigator Role:
Principal Investigator
Investigator Affiliation:
Stanford University
Authority:
United States: Institutional Review Board
Study ID:
HEP0006
NCT ID:
NCT00373347
Start Date:
November 2004
Completion Date:
December 2018
Related Keywords:
- Liver Cancer
- Carcinoma
- Liver Neoplasms
- Carcinoma, Hepatocellular
Name | Location |
|---|---|
| Stanford University School of Medicine | Stanford, California 94305-5317 |
